(Q40204887)

18 September 2017

1 reference

title

The role of progestins and progesterone receptors in the treatment of breast cancer (English)

1 reference

18 September 2017

Sedlacek SM

1

1 reference

PubMed ID

6400150

18 September 2017

Horwitz KB

series ordinal

2

1 reference

18 September 2017

1 December 1984

1 reference

18 September 2017

1 reference

18 September 2017

44

1 reference

18 September 2017

6

1 reference

18 September 2017

467-484

1 reference

18 September 2017

Cancer statistics, 1985

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Probabilities of eventually developing or dying of cancer--United States, 1985.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Hormones in breast metastasis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Hormonal therapy in cancer of the breast. III. Effect of progesterone on clinical course and hormonal excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Clinical and pharmacological observations of the effects of 9-alpha-bromo-11-beta-ketoprogesterone in patients with carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Hormonal treatment of metastatic carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Progesterone in the Treatment of Advanced Malignant Tumours of Breast, Ovary and Uterus

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

THE VALUE OF NORETHISTERONE ACETATE IN THE TREATMENT OF ADVANCED CARCINOMA OF THE BREAST

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Progestin therapy of breast cancer: comparison of agents

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Hormonal therapy in cancer of the breast. XXIV. Effect of corticosterone or medroxyprogesterone acetate on clinical course and hormonal excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Treatment of breast cancer with medroxyprogesterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Clinical trial of Δ1-testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer:A report of the cooperative breast cancer group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Progestagens and advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Norethisterone acetate (SH420) in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Norethisterone acetate in the treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Progestin therapy in advanced breast cancer: megestrol acetate--an evaluation of 160 treated cases

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Estradiol and progesterone receptors content and response to norethisterone treatment in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Therapeutic Activity of Medroxyprogesterone Acetate in Metastatic Breast Cancer: A Correlation Between Estrogen Receptors and Various Dosages

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Megestrol acetate therapy for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Advanced breast cancer: response to high dose oral medroxyprogesterone acetate.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

High Dose Medroxyprogesterone-Acetate Treatment in Advanced Mammary Carcinoma: A Phase II Investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

[Combined chemotherapy and anti-oestrogen administration for metastasising breast carcinoma: randomised study comparing AVC and AVC plus tamoxifen (author's transl)]

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer: A prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Combined chemo- and hormonal therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Combined cytotoxic and progestogen therapy for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Steroid receptors and response to endocrine treatment and chemotherapy of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Relation of tumor content of estrogen and progesterone receptors with response of patient to endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

The value of progesterone receptor assays in the management of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

The value of estrogen and progesterone receptors in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Analysis of estradiol and progesterone receptors in early and advanced breast tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Comparison of sex steroid receptor analyses and carcinoembryonic antigen with clinical response to hormone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Oestrogen and progesterone receptors and response to endocrine therapy in Japanese breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

The clinical value of multiple steroid receptor assays in breast cancer management

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Predicting treatment response in breast cancer using urinary discriminant ratio and receptor assay

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Progesterone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Evidence that estrogen-receptor-negative, progesterone-receptor-positive breast and ovarian carcinomas contain estrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Progesterone receptors as a prognostic factor in Stage II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

Prognostic value of estrogen and progesterone receptors in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2884%2980029-X

7 January 2021

10.1016/S0039-128X(84)80029-X

Identifiers

DOI

1 reference

18 September 2017

1 reference

PubMed ID

6400150